What A.L.S. and Alzheimer’s Drug Approvals Have in Commonnews2022-10-14T19:10:06+00:00October 14th, 2022|The New York Times|
F.D.A. Confirms Widespread Shortages of Adderallnews2022-10-13T18:04:42+00:00October 13th, 2022|The New York Times|
Price of New A.L.S. Treatment Will Be $158,000 Per Year, Maker Saysnews2022-09-30T20:16:18+00:00September 30th, 2022|The New York Times|
FDA Approves ALS Treatment Despite Questions About Effectivenessnews2022-09-29T21:14:36+00:00September 29th, 2022|The New York Times|
F.D.A. Warning on NyQuil Chicken Alerts Many to Existence of NyQuil Chickennews2022-09-21T18:34:44+00:00September 21st, 2022|The New York Times|
FDA’s Drug Industry Fees Fuel Concerns Over Influencenews2022-09-15T09:00:26+00:00September 15th, 2022|The New York Times|
FDA Approves Daxxify, a New Anti-Wrinkle Drugnews2022-09-08T16:33:25+00:00September 8th, 2022|The New York Times|
Fact-Checking Health Claims About the Inflation Reduction Actnews2022-08-20T03:38:07+00:00August 20th, 2022|The New York Times|
Samples of Popular Diabetes Drug Contain Potential Carcinogen, F.D.A. Saysnews2022-08-11T19:37:20+00:00August 11th, 2022|The New York Times|
There’s Just One Drug to Treat Monkeypox. Good Luck Getting It.news2022-08-06T13:35:35+00:00August 6th, 2022|The New York Times|
